1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Intercept rollercoaster continues with NASH, PBC updates

 
• By Mandy Jackson

Intercept Pharmaceuticals fell 30.1% to $172.59 per share on 7 November after data from the Phase II FLINT clinical trial for obeticholic acid (OCA) were published in The Lancet, but the update provided little new information about the drug's safety and efficacy in non-alcoholic steatohepatitis (NASH).

Intercept Pharmaceuticals fell 30.1% to $172.59 per share on 7 November after data from the Phase II FLINT clinical trial for obeticholic acid (OCA) were published in The Lancet, but the update provided little new information about the drug's safety and efficacy in non-alcoholic steatohepatitis (NASH).

Investors cut $74.39 from Intercept's stock price and chopped $1.6bn from the New York-based company's market cap after investigators from the National Institute of Diabetes and Digestive and Kidney...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

More from Therapy Areas

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 
• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.